ClinicalTrials.gg
RecruitingNCT04688736Updated Nov 12, 2026

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

A Phase 2 interventional study of Placebo and Chlorpheniramine in Allergic Transfusion Reaction, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6,642
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

02

Conditions studied

  • Allergic Transfusion Reaction

Browse trials for

Keywords

  • pretransfusion medication
  • Chlorpheniramine
  • blood transfusion
  • allergic transfusion reaction
03

In context

Transfusion Reaction

56 studies on the registry are indexed under Transfusion Reaction; 12 are open to participants now.

This study's planned enrollment of 6,642 is above the median of 71 across 23 interventional studies indexed under Transfusion Reaction.

Browse Transfusion Reaction studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18\~65 years old.
  • Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis , fresh frozen plasma) transfusions.
  • Subject can fully understand and voluntarily sign forms.

Exclusion criteria

Exclusion Criteria:

  • Subject with a history of allergic diseases.
  • Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
  • Subject received or allergy drugs within 24 hours before blood transfusion.
  • Subject transfused with washed RBC.
  • Received transplantation before.
  • Subject with heart failure.
  • Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
  • Pregnant or nursing women.
  • Inability to understand or to follow study procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,642 participants (estimated)

Study arms

  • Experimental
    Placebo

    Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.

    Drug: Placebo

  • Active comparator
    Chlorpheniramine

    Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.

    Drug: Chlorpheniramine

Interventions

  • DrugPlacebo

    The tablet resembles chlorpheniramine but has no therapeutic value.

  • An antihistamine that reduces the natural chemical histamine in the body.

06

What researchers measure

Primary outcomes

  1. The rate of allergic-transfusion reactions

    Time frame: within 4 hours from the start of the transfusion

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2020
First posted
Dec 30, 2020
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04688736
Responsible party
Sponsor
First posted
Dec 30, 2020
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jun Shi, PhD
Contact
shijun@ihcams.ac.cn
(86)2223900913
Jingyu Zhao, MPH
Contact
zhaojingyu@ihcams.ac.cn
(86)13752253515

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion